Moreover, emerging preclinical evidence has demonstrated that TNBC cells showed higher sensitivity to the c-SRC inhibitor than do other cancer subgroups by targeting BCSCs [27–30], further highlighting the potential significance of targeting BCSCs through inhibiting SRC activity in TNBC treatment. The gene discussed is SRC; the disease is cancer.